MedTrace Logo

Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants

NCT00360256 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2012-04-19

No results posted yet for this study

Summary

The objective of this pilot study is to determine the genetic polymorphism rate of CYP450 2D6 and 2C19 metabolic enzymes in patients with significant adverse effects from antidepressants, compared to a population of patients who had no significant adverse effects from antidepressants metabolized by CYP2D6 and 2C19.

The hypothesis for the proposed research is that the rate of 2D6 and 2C19 alleles that are associated with poor metabolizer status in the treatment-intolerant population will far exceed the rate found in patient population who takes antidepressants without adverse effects.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Adriana E. Foster, M.D. · Assistant Professor of Psychiatry MCG

  • Zixuan Wang, Ph.D. · Assistant Research Scientist MCG Dept of Pathology

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00360256 on ClinicalTrials.gov